

## [291] PERSONALIZED NUTRITION IN DIABETES - FOOD AS MEDICINE

Yael Glassman<sup>1</sup>, <sup>1</sup> Nutrino Health Ltd.

- **Investment Rational**  
Nutrino is a personalized nutrition insights platform optimized to support the unique needs of people living with Diabetes. Nutrino's partners include Medtronic, IBM Watson, Welltok and the Institute for Functional Medicine. Nutrino's underlying technology is called FoodPrint. It uses predictive analytics to understand how foods affect individuals utilizing collected data from medical devices, wearable devices, activity sensors, and other biomarkers.
- **Business Strategy**  
Nutrino's focus is on the Diabetes market and the company sells through channels - B2B2C. Currently, Nutrino has partnered with key multinationals -- Medtronic, IBM Watson and Welltok. Nutrino's FoodPrint platform is offered as an API or as a paid App
- **Core Technology**  
FoodPrint provides personalized and contextual food suggestions to drive better eating choices. At the core of FoodPrint is Nutrino's food analysis system and its personal profiling technology. The platform leverages techniques from optimization theory, machine learning, and big data to better understand the foods that people eat, and how those foods affect people on an individual basis.
- **Product Profile/Pipeline**  
FoodPrint was initially marketed through the App store to the general wellness market, later it was adopted by the Employer/payer market through Nutrino's collaboration with Welltok. Nutrino then began serving patients who take insulin and the company's next target is people living with Type 2 Diabetes. On the technology side, the company is expanding from CGM to BGM and Nutrigenomics. Several new partnerships are in place but are yet to be announced

### **What's Next?**

Next up is broad commercialization of the company's Type 2 offering to be announced in the coming months alongside with additional key partners in the Diabetes space and the food ecosystem space.